A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the ...

Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact aiming to ...

Medical device manufacturer Exactech has agreed to pay $8 million to settle allegations that it concealed defects in a ...

It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition of Carmot ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Biotech entrepreneurship must run in the blood for the Langers.   | Renowned biotech veteran Robert Langer is the executive ...

GE HealthCare is reportedly weighing the sale of a stake in its China division, which maintains about 7,000 employees across ...

Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ...

Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.

One of the top fundraisers of 2024 is halving its workforce about a year after drawing in a $325 million series C. | One of ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 ...

As the financial ramifications of federal research cuts come into focus, several organizations are warning of the looming ...